Predictors of response to pacritinib therapy and survival among 60 Mayo Clinic patients with myelofibrosis treated outside of clinical trials
Not available.
Saved in:
| Main Authors: | Maymona Abdelmagid, Jeanne M. Palmer, Aref Al-Kali, Mehrdad Hefazi, James Foran, Kebede H. Begna, Cecilia Y. Arana Yi, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-03-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/11997 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons
by: Naseema Gangat, et al.
Published: (2025-05-01) -
Cytogenetic abnormalities in polycythemia vera: phenotypic correlates and prognostic relevance in 669 informative cases
by: Moazah Iftikhar, et al.
Published: (2025-03-01) -
Basophilia and eosinophilia in primary myelofibrosis: phenotype, genotype, and prognostic correlates
by: Sarah Dingli, et al.
Published: (2025-04-01) -
<i>CSF3R</i> mutations and variants in myeloid neoplasms: associated phenotypes, co-mutations, and survival trends
by: Abiola Bolarinwa, et al.
Published: (2025-07-01) -
Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days
by: Naseema Gangat, et al.
Published: (2025-04-01)